- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 910KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 503KB)
Tagraxofusp – July 2023
Tagraxofusp: Solution concentrate for I.V. infusion 1 mg in 1 mL; Elzonris® - July 2023
Last updated
10 November 2023